Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward Phase 2 clinical trials after Phase 1 studies demonstrated a favorable safety profile. The therapy is designed to target demyelination and protect or restore myelin integrity, offering a potentially first-in-class approach that directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation.
In April 2026, the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 19.84% as of March 31, 2026. The agreement includes royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For more information, visit the company’s newsroom at https://ibn.fm/QNTM. The full article can be viewed at https://ibn.fm/AUhNl.
